MYO10 and Mitochondrial Transfer in Neurodegeneration

MYO10 and Mitochondrial Transfer in Neurodegeneration

Overview

MYO10 (Myosin X) is an unconventional myosin mo[@kawasaki2023]tor protein highly expressed in human satellite glial cells (SGCs) that plays a critical role in mitochondrial transfer to neurons. Disruption of this pathway leads to nerve degeneration and neuropathic pain, making it a novel therapeutic target for neurodegeneration.[@gomez2021] This mechanism represents a fundamental metabolic support system in the peripheral nervous system with implications for understanding and treating various neurological conditions [1].

The discovery of MYO10-mediated mitochondrial transfer has revealed a previously unrecognized pathway for neuronal metabolic support. Unlike central nervous system astrocytes which transfer mitochondria through various mechanisms, peripheral sensory neurons rely heavily on SGC-derived mitochondrial support for maintaining metabolic homeostasis [2]. This distinction has important implications for understanding peripheral neuropathies and developing targeted therapies.

Molecular Biology of MYO10

Structure and Function

MYO10 belongs to the unconventional myosin family, characterized by motor activity that uses ATP to generate force along actin filaments. Unlike conventional myosins that primarily function in muscle contraction and cellular transport, MYO10 possesses unique structural features that enable its specialized functions:

MYO10 and Mitochondrial Transfer in Neurodegeneration

Overview

MYO10 (Myosin X) is an unconventional myosin mo[@kawasaki2023]tor protein highly expressed in human satellite glial cells (SGCs) that plays a critical role in mitochondrial transfer to neurons. Disruption of this pathway leads to nerve degeneration and neuropathic pain, making it a novel therapeutic target for neurodegeneration.[@gomez2021] This mechanism represents a fundamental metabolic support system in the peripheral nervous system with implications for understanding and treating various neurological conditions [1].

The discovery of MYO10-mediated mitochondrial transfer has revealed a previously unrecognized pathway for neuronal metabolic support. Unlike central nervous system astrocytes which transfer mitochondria through various mechanisms, peripheral sensory neurons rely heavily on SGC-derived mitochondrial support for maintaining metabolic homeostasis [2]. This distinction has important implications for understanding peripheral neuropathies and developing targeted therapies.

Molecular Biology of MYO10

Structure and Function

MYO10 belongs to the unconventional myosin family, characterized by motor activity that uses ATP to generate force along actin filaments. Unlike conventional myosins that primarily function in muscle contraction and cellular transport, MYO10 possesses unique structural features that enable its specialized functions:

• Motor Domain: Contains the ATP-binding site and actin-binding region essential for force generation
• Tail Domain: Includes a coiled-coil region for dimerization and a specific motif for cargo binding
• PH Domain: Pleckstrin homology domain enables membrane localization and phosphoinositide binding

Expression Patterns

MYO10 demonstrates remarkable specificity in its expression pattern:

• Human SGCs: High expression in human dorsal root ganglion and trigeminal ganglion SGCs
• Mouse SGCs: Low or undetectable expression, explaining species-specific phenotypes
• CNS: Minimal expression in central nervous system glial cells
• Neurons: Low baseline expression, but can be upregulated under stress conditions

The MYO10-Mitochondrial Transfer Pathway

Satellite Glial Cells and Mitochondrial Trafficking

Satellite glial cells (SGCs) are specialized glial cells that ensheath sensory neurons in peripheral ganglia (dorsal root ganglia, trigeminal ganglia). They provide metabolic support and communicate with neurons through various mechanisms, including direct mitochondrial transfer.[@hanani2020] Each sensory neuron in peripheral ganglia is surrounded by multiple SGCs that form a tight envelope, creating a unique microdomain for neuron-glia communication [5].

The SGC-neuron relationship in peripheral ganglia parallels the astrocyte-neuron relationship in the CNS but with distinct mechanistic features. SGCs respond to neuronal activity, undergo morphological changes, and provide feedback to neurons through various signaling molecules including ATP, glutamate, and cytokines [6].

MYO10 is a motor protein that:

• localizes to the soma of SGCs
• associates with mitochondria via adaptor proteins
• enables actin-based mitochondrial transport along SGC processes
• facilitates transfer of functional mitochondria to adjacent neurons

Mechanism of Transfer

The transfer process involves several key steps:

Role in Neurodegeneration

Evidence from Research

• Neuronal ATP depletion
• Calcium dysregulation
• Oxidative stress
• Axonal degeneration
• Neuropathic pain behaviors

Alzheimer's Disease

While MYO10 research has focused primarily on peripheral nervous system disorders, the fundamental mechanisms have implications for AD:

• Metabolic Support Failure: Impaired mitochondrial transfer may contribute to neuronal metabolic deficits observed in AD [11]
• Glial-Neural Interactions: Understanding CNS parallels may reveal therapeutic targets
• Calcium Dysregulation: Disrupted mitochondrial calcium handling contributes to AD pathogenesis [12]

Parkinson's Disease

The mitochondrial dysfunction paradigm in PD intersects with SGC-mitochondrial transfer:

• Metabolic Stress: PD neurons face chronic metabolic stress that may be exacerbated by impaired support
• Alpha-Synuclein Effects: Mitochondrial quality control is critical for PD pathogenesis
• Peripheral Manifestations: Some PD patients develop peripheral neuropathy that may involve SGC dysfunction [13]

Amyotrophic Lateral Sclerosis

ALS affects both central and peripheral nervous systems:

• Metabolic Support: Motor neuron survival depends on adequate metabolic support
• Glial Contributions: SGC dysfunction may contribute to sensory symptoms in ALS
• Mitochondrial Quality Control: Defects in mitochondrial dynamics are central to ALS pathogenesis [14]

Peripheral Neuropathy

The MYO10 pathway is most directly relevant to peripheral neuropathy:

| Condition | MYO10 Pathway Relevance |
|-----------|------------------------|
| Diabetic Neuropathy | Hyperglycemia impairs SGC mitochondrial transfer |
| Chemotherapy-induced | Taxanes and platinum drugs disrupt mitochondrial dynamics |
| Chronic Inflammatory | Inflammatory cytokines affect SGC function |
| Hereditary | Some inherited neuropathies involve mitochondrial dysfunction |

Therapeutic Implications

Targeting the MYO10 Pathway

Delivery Considerations

• Peripheral nervous system targeting (local injection to affected ganglia)
• Must cross the blood-nerve barrier
• May require nerve growth factor or similar enhancers for SGC accessibility

Research Challenges

• Species differences between human and rodent models complicate translation
• Limited understanding of the precise transfer mechanism
• Delivery to specific ganglia while minimizing systemic effects

Cross-Links

Related Mechanisms

• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
• [Tunneling Nanotubes](/mechanisms/tunneling-nanotubes) — another intercellular mitochondrial transfer mechanism
• [Astrocyte-Neuron Metabolic Coupling](/hypotheses/astrocyte-neuron-metabolic-coupling-parkinsons)

Related Therapies

• [Mitochondrial Transplantation](/therapeutics/mitochondrial-transplantation-neurodegeneration)
• [Mesenchymal Stem Cell Therapy](/therapeutics/mesenchymal-stem-cell-therapy-neurodegeneration)
• [Astrocytic Mitochondrial Transfer Therapy](/therapeutics/astrocytic-mitochondrial-transfer-therapy)

Related Genes

• [MYO5A](/genes/myo5a) — related myosin involved in organelle transport
• [MYO6](/genes/myo6) — another unconventional myosin with neuronal functions

See Also

• [Neuropathic Pain Mechanisms](/mechanisms/neuropathic-pain-pathways)
• [Peripheral Neuropathy](/diseases/peripheral-neuropathy)
• [Satellite Glial Cells](/cell-types/satellite-glial-cells)

References

Animal Models and Research Tools

Current Model Systems

Understanding MYO10-mediated mitochondrial transfer has been hampered by the species-specific expression pattern. Researchers have developed several approaches to overcome this limitation:

Humanized Mouse Models: Transgenic mice expressing human MYO10 under SGC-specific promoters have been developed to study the pathway. These models recapitulate the human pattern of SGC mitochondrial transfer and enable therapeutic testing [15].

In vitro Systems: Primary cultures of human dorsal root ganglion SGCs provide a tractable system for mechanistic studies. Co-culture systems with neurons allow visualization of mitochondrial transfer through live-cell imaging [16].

Organotypic Cultures: Explant cultures of peripheral ganglia maintain the native SGC-neuron architecture while enabling experimental manipulation. This approach has been particularly valuable for studying injury responses [17].

Imaging Approaches

Visualizing mitochondrial transfer requires specialized techniques:

• Confocal Microscopy: Time-lapse imaging of fluorescently labeled mitochondria in co-cultures
• Super-Resolution Microscopy: PALM/STORM imaging of MYO10 localization
• Electron Microscopy: Serial block-face EM to capture mitochondrial contacts between SGCs and neurons
• Fluorescence Recovery After Photobleaching (FRAP): Quantifies functional mitochondrial transfer

Genetic Models

| Model | Application | Limitations |
|-------|-------------|-------------|
| MYO10 knockout mice | Loss-of-function studies | Limited SGC expression |
| MYO10 floxed mice | Conditional deletion | Requires SGC-specific Cre |
| Human MYO10 transgenic | Human pathway reconstruction | May not fully recapitulate human context |
| Miro1 conditional knockout | Downstream pathway | Affects multiple cell types |

Biomarkers and Diagnostic Applications

Clinical Biomarkers

While MYO10 research remains primarily in the preclinical realm, several biomarker approaches are being developed:

SGC-Derived Markers: Circulating SGC-derived extracellular vesicles may provide information about SGC function. These vesicles contain mitochondrial proteins and SGC-specific transcripts that could serve as biomarkers [18].

Functional Assessments: Quantitative sensory testing (QST) can identify small fiber dysfunction that may correlate with impaired mitochondrial transfer. Thermal threshold testing is particularly relevant [19].

Imaging Markers: Advanced MRI techniques including diffusion tensor imaging may detect peripheral nerve pathology. PET imaging of mitochondrial function is under development [20].

Research Biomarkers

For clinical research and clinical trials:

• MYO10 expression in sural nerve biopsies
• Mitochondrial function in skin fibroblasts
• ATP levels in peripheral blood mononuclear cells

Clinical Implications

Patient Populations

The MYO10 pathway is relevant to several patient populations:

| Condition | Pathway Relevance | Potential Intervention |
|-----------|-------------------|----------------------|
| Diabetic Peripheral Neuropathy | Hyperglycemia impairs SGC function | Glycemic control, SGC-protective agents |
| Chemotherapy-induced Neuropathy | Direct mitochondrial toxicity | Mitochondrial protectants |
| Chronic Pain States | Sustained SGC activation | Anti-inflammatory approaches |
| Aging-related Neuropathy | Declining MYO10 expression | Age-appropriate interventions |
| Inflammatory Neuropathies | Cytokine-mediated SGC dysfunction | Immunomodulation |

Therapeutic Development

Several therapeutic modalities are being explored:

Current Research Status

The field is in early stages of therapeutic development:

• Preclinical proof-of-concept demonstrated in animal models
• No clinical trials currently targeting the MYO10 pathway specifically
• Research focused on understanding basic mechanisms and identifying therapeutic candidates

Future Directions

Key Questions

Several critical questions remain to be addressed:

Emerging Areas

• Single-Cell Sequencing: Profiling of SGCs from different neuropathic conditions to understand disease-specific changes
• Spatial Transcriptomics: Mapping of MYO10 expression in human peripheral ganglia
• Organoid Models: Development of peripheral ganglion organoids to study human-specific mechanisms
• Clinical Correlates: Establishing patient cohorts with peripheral neuropathy for biomarker studies

Integration with CNS Research

While MYO10 is primarily studied in the peripheral nervous system, parallels with CNS mitochondrial transfer are emerging. Understanding the similarities and differences between peripheral and central mechanisms may lead to broadly applicable therapeutic approaches.

Additional Disease Connections

Multiple Sclerosis

Multiple sclerosis (MS) involves demyelination and axonal degeneration in the CNS, but peripheral nervous system involvement is also recognized:

• SGC Dysfunction in MS: Sensory symptoms in MS may involve SGC dysfunction secondary to central pathology
• Mitochondrial Protection: Enhancing mitochondrial transfer may protect sensory neurons from secondary degeneration
• Therapeutic Potential: SGC-targeted therapies could complement CNS-directed approaches in MS [21]

Charcot-Marie-Tooth Disease

Charcot-Marie-Tooth (CMT) disease is the most common inherited peripheral neuropathy, with several subtypes involving mitochondrial dysfunction:

• CMT2A (MFN2): Mutations in mitofusin 2 affect mitochondrial dynamics and may impact SGC-neuron interactions
• CMT1A (PMP22): Demyelinating neuropathy with secondary axonal involvement
• CMT2 (Axonal): Primary axonal degeneration where SGC support becomes critical
• Therapeutic Implications: Enhancing SGC mitochondrial transfer could compensate for intrinsic neuronal mitochondrial defects [22]

Guillain-Barré Syndrome

Guillain-Barré syndrome (GBS) is an autoimmune peripheral neuropathy that may involve SGC dysfunction:

• Autoimmune Attack: Antibodies target peripheral nerve components including SGCs
• Inflammatory cytokines: Released during immune response affect SGC function
• Recovery Phase: SGC-mediated repair may determine functional recovery
• Therapeutic Implications: Immunomodulation plus SGC support may enhance recovery [23]

Molecular Mechanisms

Signaling Pathways

Several signaling pathways regulate MYO10 expression and mitochondrial transfer:

| Pathway | Effect on MYO10 Pathway | Therapeutic Target |
|---------|------------------------|---------------------|
| cAMP/PKA | Upregulates MYO10 expression | PKA agonists |
| PI3K/Akt | Enhances mitochondrial loading | Akt activators |
| MAPK/ERK | Modulates SGC activation | MEK inhibitors |
| JAK/STAT | Regulates inflammatory response | JAK inhibitors |
| AMPK | Energy sensing, affects transfer | AMPK activators |

Cytoskeletal Dynamics

The actin cytoskeleton is central to MYO10 function:

• Actin Polymerization: Formins and Arp2/3 complex regulate actin dynamics
• Myosin Regulation: MYO10 activity is modulated by light chain phosphorylation
• Cargo Adaptors: Miro1/2 connect mitochondria to motor proteins
• Pathway Implications: Targeting cytoskeletal components may enhance transfer efficiency [24]

Calcium Signaling

Calcium dynamics regulate mitochondrial transfer:

• SGC Calcium: Activity-dependent calcium changes in SGCs
• Neuronal Calcium: Calcium transients in neurons signal mitochondrial need
• Intercellular Calcium Waves: Calcium signaling between SGCs and neurons coordinates transfer
• Therapeutic Modulation: Calcium channel modulators may enhance transfer [25]

Comparative Biology

Evolutionary Perspective

Mitochondrial transfer mechanisms have evolved across species:

• Mammals: SGC-mediated transfer in peripheral ganglia
• Birds: Similar SGC architecture but different myosin expression
• Fish: Lateral line system with supporting cells
• Invertebrates: Analogous glial support in certain ganglia

Species-Specific Considerations

The species difference in MYO10 expression has important implications:

• Translational Research: Murine models require humanized approaches
• Drug Testing: Efficacy in human SGCs may not be captured in mouse models
• Biomarker Development: Human tissue validation essential
• Therapeutic Development: Species-specific considerations in drug design

Clinical Management

Diagnostic Evaluation

Patients with suspected SGC-mitochondrial transfer dysfunction may benefit from:

• Detailed sensory history
• Quantitative sensory testing
• Nerve conduction studies
• Skin biopsy for intraepidermal nerve fiber density

• Glucose and HbA1c
• Vitamin B12 and folate
• Autoimmune panels when indicated
• Genetic testing for inherited neuropathies

• Corneal confocal microscopy for small fibers
• Nerve ultrasound
• MR neurography

Management Strategies

Based on current understanding of MYO10 pathway:

| Approach | Mechanism | Evidence Level |
|----------|-----------|----------------|
| Metformin | AMPK activation, enhances mitochondrial function | Preclinical |
| Acetyl-L-carnitine | Mitochondrial energy support | Clinical (mixed) |
| Alpha-lipoic acid | Antioxidant, mitochondrial support | Clinical (moderate) |
| Physical therapy | Activity enhances mitochondrial dynamics | Clinical |
| glycemic control | Reduces SGC dysfunction in diabetes | Clinical (strong) |

Future Therapeutic Approaches

Several emerging therapies may target the MYO10 pathway:

• MYO10-targeted small molecules in development
• Gene therapy vectors for SGC-specific delivery
• Cell therapy using SGC-like cells
• Biologics targeting SGC-neuron communication